IVVD

Invivyd, Inc. is a biopharmaceutical company dedicated to protecting vulnerable populations from serious viral infectious diseases. The company focuses on developing antibody-based therapies for infectious diseases, with an initial emphasis on COVID-19 and influenza. Invivyd's platform combines expertise in antibody discovery, engineering, and clinical development to create potent and durable antiviral therapies. The company was spun out from AstraZeneca's long-acting antibody program and continues to advance next-generation antibody treatments designed to address evolving viral threats.